COVID-19 AND CARDIOVASCULAR STORM

  • Marina Catalina ARSENESCU GEORGESCU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • M.A ZAVALICHI “Grigore T. Popa” University of Medicine and Pharmacy Iasi
Keywords: COVID-19, CARDIOVASCULAR STO

Abstract

COVID-19 pandemic is one of the biggest challenges confronting communities and nations, having a tremendous impact on public health services all over the world. In the past years, people have faced several worldwide epidemic infections, such as Severe Acute Respiratory Syndrome (SARS), avian influenza, influenza, but SARS-Cov-2 is rapidly becoming the most threatening global enemy, endangering not only the health systems' stability, but transforming into a social and economic crisis.

Author Biographies

Marina Catalina ARSENESCU GEORGESCU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Cardiology and Cardiovascular Surgery

M.A ZAVALICHI, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Cardiology and Cardiovascular Surgery

References

1. Cheng VC, Lau SK, Woo PC, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 2007; 20(4): 660‐694.
2. Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348(20): 1967‐1976.
3. He F, Deng Y, Li W. Coronavirus disease 2019: What we know? J Med Virol 2020; 1-7.
4. Gurtoo A, Agrawal A, Prakash A, et al. The Syndromic Spectrum of COVID-19 and Correlates of Admission Parameters with Severity-outcome Gradients: A Retrospective Study. J Assoc Physicians India 2020; 68(12): 43-48.
5. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149(3 Pt 1): 818-824.
6. Chen C, Zhou, Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocardi-tis. Herz 2020; 45(3): 230-232.
7. He XW, Lai JS, Cheng J. Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients. Zhonghua Xin Xue Guan Bing Za Zhi 2020; 48(6): 456-460.
8. Miftode E, Luca C, Manciuc C, et al. COVID-19: A course through stormy waters. Rev Med Chir Soc Med Nat Iasi 2020; 124(3): 351-362.
9. Khan MMA, Khan MN, Mustagir MG, Rana J, Islam MS, Kabir MI. Effects of underlying morbidities on the occurrence of deaths in COVID-19 patients: A systematic review and meta-analysis. J Glob Health 2020; 10(2): 020503.
10. Bozkurt B, Kovacs R, Harrington B. Joint HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. J Card Fail 2020; 26(5): 370-374.
11. Kurdi A, Abutheraa N, Akil L, Godman B. A systematic review and meta-analysis of the use of renin-angiotensin system drugs and COVID-19 clinical outcomes: What is the evidence so far ? Pharmacol Res Perspect 2020; 8(6): e00666.
12. Bienvenu LA, Noonan J, Wang X, Peter K. Higher mortality of COVID-19 in males: sex differences in immune response and cardiovascular comorbidities. Cardiovasc Res 2020; 116(14): 2197-2206.
13. Mackey K, Ayers CK, Kondo KK, et al. Racial and Ethnic Disparities in COVID-19-Related Infections, Hospitalizations, and Deaths: A Systematic Review. Ann Intern Med 2020.
14. Belkaid Y, Rouse BT. Natural regulatory T cells in infectious disease. Nat Immunol 2005; 6(4): 353-360.
15. Boisrame-Helms J, Kremer H, Schini-Kerth V, Meziani F. Endothelial dysfunction in sepsis. Curr Vasc Pharmacol 2013; 11: 150-160.
16. Zhou F, Yu T, Du R, et al. Clinical course, and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395(10229): 1054-1062.
17. Rodríguez C, Luque N, Blanco I, et al. Pulmonary Endothelial Dysfunction and Thrombotic Complica-tions in COVID-19 Patients. Am J Respir Cell Mol Biol 2020.
18. Krishnamachary B, Cook C, Spikes L, et al. The Potential Role of Extracellular Vesicles in COVID-19 Associated Endothelial injury and Pro-inflammation. medRxiv Prepr Serv Heal Sci 2020.
19. Cribbs SK, Martin GS, Rojas M. Monitoring of endothelial dysfunction in critically ill patients: The role of endothelial progenitor cells. Curr Opin Crit Care 2008; 14: 354-360.
20. Statescu C, Sascau R, Anghel L, Butcovan D. Morphological diagnosis of myocardial infarction- in the light of the current clinical classification. Rev Med Chir Soc Med Nat Iasi 2019; 123(4): 708-716.
21. Bangalore S, Sharma A, Slotwiner A, et al. ST-segment elevation in patients with COVID-19 - a case series. N Engl J Med 2020; 382: 2478-2480.
22. Bois MC, Boire NA, Layman AJ, et al. COVID-19-associated Non-Occlusive Fibrin Microthrombi in the Heart. Circulation 2020.
23. Giustino G, Croft LB, Stefanini GG, et al. Characterization of Myocardial Injury in Patients With COVID-19. J Am Coll Cardiol 2020; 76(18): 2043-2055.
24. Shchedrygina A, Nagel E, Puntmann VO, Valbuena-Lopez S. COVID-19 myocarditis and prospective heart failure burden. Expert Rev Cardiovasc Ther 2020; 1-10.
25. ***The European Society for Cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance. (Last update: 10 June 2020).
26. Abapoor-Farrokhran S, Rasekhi RT, Gill D, et al. Arrhythmia in COVID-19. SN Compr Clin Med 2020; 2: 1430-1435.
27. Eckart RE, Shry EA, Burke AP, et al. Sudden death in young adults: an autopsy-based series of a population undergoing active surveillance. J Am Coll Cardiol 2011; 58: 1254-1261.
28. Babapoor-Farrokhran S, Gill D, Walker J, Rasekhi RT, Bozorgnia B, Amanullah A. Myocardial injury, and COVID-19: Possible mechanisms. Life Sci 2020; 253: 117723.
29. Ammirati E, Cipriani M, Lilliu M, Sormani P, Varrenti M, Raineri C, et al. Survival and Left Ventricu-lar Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis. Circulation 2017; 136: 529-545.
30. McCarthy RE 3rd, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000; 342: 690-695.
31. Teuwen LA, Geldhof V, Pasut A, Carmeliet P. COVID-19: the vasculature unleashed. Nat Rev Immunol 2020; 20: 389-391.
32. Zeng JH, Liu Y, Yuan J, et al. First Case of COVID-19 Infection with Fulminant Myocarditis Com-plication: A Case Report and Insights. Infection 2020; 48(5): 773-777.
33. Huang L, Zhao P, Tang D, et al. Cardiac involvement in recovered COVID-19 patients identified by magnetic resonance imaging. J Am Coll Cardiol Img 2020.
34. Fabre O, Rebet O, Carjaliu I, Radutoiu M, Gautier L, Hysi I. Severe Acute Proximal Pulmonary Embo-lism and COVID-19: A Word of Caution. Ann Thorac Surg 2020; 110(5): e409-e411.
35. Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicine 2020; 29: 100639.
36. Linschoten M, Peters S, van Smeden M, et al. Cardiac complications in patients hospitalized with COVID-19. Eur Heart J Acute Cardiovasc Care 2020.
37. Wu T, Zuo Z, Yang D, et al. Venous thromboembolic events in patients with COVID-19: A systematic review and meta-analysis. Age Ageing 2020.
38. Mir T, Attique HB, Sattar Y, et al. Does pulmonary embolism in critically ill COVID-19 patients worsen the in-hospital mortality: A meta-analysis. Cardiovasc Revasc Med 2020; S1553-8389(20): 30780-30786.
Published
2020-12-23